

21 November 2014 EMA/HMPC/638812/2014 Procedure Management and Business Support Division

Committee on Herbal Medicinal Products (HMPC)

Agenda of the 24 November 2014 meeting

24 November 2014, 09:00 – 19:00, room 3E, *plenary* (Assessors training on 25 November 2014, 09:00-17:00, 3E)

Chair: Werner Knöss

• Health & Safety Information

In accordance with Agency policy, delegates are to be shown a slide show with health and safety and emergency information and procedures. This is to be displayed at the start of this meeting using the Creston system as delegates are entering the meeting room. In addition, the meeting secretariat is to draw the delegates' attention to the slideshow and point out the nearest fire exit(s), which are marked where the room has two or more exits. Should there be an evacuation during the meeting staff will guide delegates out of the building via the nearest fire exit.

• Welcome to new participants

new trainee at the B-CS-SCS

• Announcement of new nominations, changes to composition

Resignation of Mariette Backes-Lies (LU member)

• Election of Co-opted member to the HMPC with expertise in:

- Paediatric medicine See I.1.3

• Declaration of conflict of interests

In accordance with the Agency's Policy and Procedure on the handling of conflicts of interests, participants in this meeting are asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting will take place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee secretariat at the start of the meeting.

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



 ${\ensuremath{\mathbb C}}$ European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.

d anna dala dala a anna da a dua cuda da a d

An agency of the European Union

• Draft annex to the minutes for the November 2014 HMPC meeting, documenting anticipated restriction on involvement in relation to agenda topics and declarations of interest from members and alternates (EMA/HMPC/639151/2014)

• Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present within the framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents .

* = Change introduced after

I. Introduction		
I.1 Agenda, minutes		
I.1.1 Agenda of 24 November 2014 HMPC meeting - timetable, for order of topics For adoption		
I.1.2 Minutes of 29-30 September HMPC meeting For adoption		
 I.1.3 Election of co-opted member procedure for nomination/election of co-opted members for HMPC Overview of expertise available in the HMPC, MLWP, ORGAM, Q DG Nomination received for Paediatric medicine 	Report: HMPC Chair	
For adoption		
I.2 Legislation and regulatory affairs		
 I.2.1 Revision procedure for List entries email from legal department 7 November 2014 draft list of minor/major changes For discussion 	See also I.6 and V.1.3	
I.2.2 New terminology for herbal monographs and list entries - email from legal department 8 October 2014 For information		
I.3 Questions raised by HMPC members		
I.4 Questions raised by companies		
I.5 Referral procedures		
I.6 Co-ordination with Eur. Com.		
I.6.1 Revision procedure for List entries	Report: E. van Galen	
For discussion	See I.2.1 and V.1.3	
I.7 Co-ordination with EFSA		

I.7.1 Report from 'HMPC strategic presidency meeting' held in Rome on 4-5 November 2014 - agenda - presentations <i>For information</i> I.8 Other external Co-ordination	Report: M. Delbó, HMPC Chair
II. Safety & efficacy	
II.1 Report on MLWP activities	
II.1.1 Report on progress achieved Overview of status of MLWP assessment work For information	Report: MLWP Chair
II.1.2 MLWP work plan 2015 For adoption	Report: MLWP Chair See V.2.1
II.2 European Union list entries transmitted to	European Commission
II.3 European Union herbal monographs for pusystematic review/revision	blic consultation/final adoption after
II.3.1 Monograph on Echinaceae purpureae herba (and supporting documents: AR, LoR) For adoption	MLWP proposed no changes to the existing LE.
II.3.2 Monograph Betulae folium (and supporting documents: AR, LoR) For adoption	Rapporteur: Peer-reviewer:
II.4 European Union herbal monographs (post	finalisation)
II.5 European Union herbal monographs, Euro for adoption after public consultation	pean Union list entries and public statements
II.5.1 Monograph and list entry on Melaleucae alternifoliae aetheroleum (and supporting documents: AR, LoR, OoC) For adoption	Rapporteur: M. Delbò Peer-reviewer: J. Viguet-Poupelloz
II.5.1 Monograph on Lichen islandicus (and supporting documents: AR, LoR, OoC) For adoption	Rapporteur: M. Heroutová Peer-reviewer: A. Vlietinck
II.6 European Union herbal monographs, European Grand Stranger Str	
II.6.1 Monograph on Carvi aetheroleum (and supporting documents: AR, LoR) For adoption	
II.6.2 Monograph on Carvi fructus (and supporting documents: AR, LoR) For adoption	See II.6.1

II.6.3 Monograph on Sabalis serrulatae fructus (and supporting documents: AR, LoR) For adoption		
II.7 European Union herbal monographs, European Union list entries and public statements		
for discussion		
II.7.1 MLWP recommendation to cancel the assessment work on Cyani flos (and supporting documents: presentation) <i>For adoption</i>		
II.7.2 MLWP recommendation to cancel the assessment work on Myrtilli folium (and supporting documents: Mo and AR <i>For adoption</i>		
II.8 Guidelines and other guidance documents		
 II.8.1 Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) final public statement overview of comments For adoption 	For final adoption.	
 II.8.2 Public statement on the use of herbal medicinal products containing estragole letter by SWP Chair draft revised public statement For adoption 	Draft adoption for public consultation.	
 II.8.3 Public statement on the use of herbal medicinal products containing pulegone and menthofuran letter by SWP Chair draft revised public statement For adoption 	<i>Draft adoption for public consultation.</i> <i>See also IV.3.1</i>	
III. Quality		
III.1 Quality Drafting Group		
III.1.1 Meeting report from Q DG meeting held on 12 November 2014 For adoption	Report: Q DG Chair	
III.1.2 'Revised Questions & answers on quality of herbal medicinal products/traditional herbal medicinal products' rev 5 For adoption	Report: Q DG Chair Postponed to January 2015	
III.1.3 Reflection paper on Benzene (class 1 solvent) as a potential impurity in solvents used for the manufacture of herbal preparations <i>For adoption</i>	Report: Q DG Chair	
medicinal products' rev 5 For adoption III.1.3 Reflection paper on Benzene (class 1 solvent) as a potential impurity in solvents used for the manufacture of herbal preparations		

III 1 5 0 DG work plan 2015	Papart: O.D.C. Chair
III.1.5 Q DG work plan 2015 For adoption	Report: Q DG Chair See V.2.1
III.2 Co-ordination European Pharmacopeia	
III.2.1 EDQM Expert Group 13A meeting to be held	EDQM: M. Bald, U. Rose
on 2-3 December 2014	HMPC Observer: I. Chinou
- agenda	
For information	
III.2.2 EDQM: 50 years of leadership in the quality of medicines – paving the way for the future	EDQM: M. Bald, U. Rose
meeting held on 6-8 October 2014	
- presentations	
For information	
III.2.3 HMPC observers at Ph. Eur. Expert groups	
13A, 13B and TCM	
-email	
For discussion	
IV. Internal Co-ordination with committee and	working parties
IV.1 Observers at other Committees	
IV.1.1 Overview of HMPC coordination/observers	
with other committees	
For discussion	
IV.2 Co-ordination with CHMP	
IV.3 Co-ordination with SWP	
IV.3.1 Revision public statement on the use of	See II.8.3
herbal medicinal products containing pulegone and	
menthofuran	
For discussion	
IV.4 Co-ordination with HCPWP/PCWP	
IV.4.1 Draft Work plan for the European Medicines	
Agency Human Scientific Committees' Working	HMPC observer: S. Bager
Party with Healthcare Professionals' Organisations	
(HCPWP)	
- presentation	
For adoption	
IV.4.2 Draft Work plan for the European Medicines	
Agency Human Scientific Committees' Working	HMPC observer: S. Bager
Party with Patients' and Consumers' Organisations	
(PCWP) 2015	
- presentation	
For adoption	

apporteurs: E. Svedlund, P. Claeson, R. Laenger,
. v. Galen ee also V.1.2
eport: ORGAM DG Chair
apporteurs: E. Svedlund, P. Claeson, R. Laenger,
. v. Galen
ee IV.5.1
eport: ORGAM DG Chair
ee I.2.1
ee V.2.2
ee also II.1.2, III.1.3 and V.1.4

V.2.4 Assessors' training 'European Union monographs- development and usages' on 25 November 2014 - agenda <i>For information</i>	Report: HMPC Chair Supported by: R. Länger, H. Neef, I. Chinou
V.2.5 Quality and finalisation of documents transmitted to HMPC for adoption - examples For discussion	
 V.2.6 Survey on implementation of Dir. 2004/24/EC (status 2014) Timetable List of questions For discussion 	
V.2.7 Minor change of time schedule for January 2015 meeting	
- email dated 18 November 2014 For discussion	
VI. Other relevant business	
VI.1 Conferences, presentations & research pre	<u>ojects</u>
VI.1.1 Paving the way towards a coherent system, AESGP meeting in Brussels 7-8 October 2014 - report	Report: W. Knöss, I. Chinou, M. Delbó
For information	http://www.aesgp.eu/media/reports/London_report.pdf
VI.2 International cooperation, collaboration w	vith non-EU regulatory authorities
VI.2.1 7th annual meeting of IRCH to be held in Lisbon, Portugal on 2-4 December 2014 - draft agenda - programme For information	Report: HMPC Chair
VI.3 Documents for information	
VI.3.1 Table of Decisions from HMPC meeting held on 29-30 September 2014	
VI.3.2 Meeting report from HMPC meeting held on 29-30 September 2014	http://www.ema.europa.eu/docs/en_GB/document_librar y/Committee_meeting_report/2014/10/WC500175755.p df
VI.3.3 Draft agenda of MLWP meeting to be held on 26 - 28 November 2014	
VI.3.4 Table of Conclusions from MLWP meeting held on 30 September – 2 October 2014 VI.3.5 Draft Minutes from MLWP meeting held on	
30 September – 2 October 2014 VI.3.6 Overview of status of HMPC assessment work – priority list	http://www.ema.europa.eu/docs/en_GB/document_librar y/Other/2009/12/WC500017724.pdf

VI.3.7 Inventory of herbal substances for assessment work	http://www.ema.europa.eu/docs/en_GB/document_librar y/Other/2009/12/WC500017723.pdf
VI.3.8 Common names of herbal substances in all EU official languages	
VI.3.9 PCWP - Training session for patients and consumers involved in EMA activities (25 November 2014) - draft agenda	Observer: S. Bager
VI.3.10 PCWP - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations (26 November 2014) - draft agenda	Observer: S. Bager
VI.3.11 News item on 10 th anniversary HMPC at the EMA website	http://www.ema.europa.eu/ema/index.jsp?curl=pages/n ews and events/news/2014/11/news detail 002211.jsp ∣=WC0b01ac058004d5c1
VI.3.12 NTP project: Report on Carcinogens (RoC) Concept: Goldenseal Root Powder	
VI.4 Any other information	
VI.4.1 Abbreviations in HMPC minutes	http://www.ema.europa.eu/docs/en_GB/document_librar y/Other/2013/11/WC500155666.pdf
VI.4.2 Proposal by Kew Gardens to map a plant listemail from M. Delbò 14 November 2014proposal from Kew Gardens	Report: M. Delbò
VI.4.3 Non-European traditional herbal medicines in Europe: A community herbal monograph perspective. L. Que <i>et al., Journal of</i> <i>Ethnopharmacology</i> 156(2014) 107–114	